Centre Hospitalier Universitaire De Lille
Centre Hospitalier Universitaire De Lille is recorded as a service provider in 4 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 4 of 4 trials · Latest update first
HOVON 173 AML: Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
Randomized study to assess revumenib in combination with azacitidine + venetoclax in adult patients with newly diagnosed NPM1-mutated or KMT2A-rearranged AML ineligible for intensive chemotherapy
Sponsor Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting
- Start (EU)
- Latest update
- Estimated end
EXL-01 in combination with nivolumab for advanced NSCLC refractory to immunotherapy'
Sponsor Centre Hospitalier Universitaire De Lille
- Start (EU)
- Latest update
- Estimated end
- Not reported
FILOAML-RR-01-OGILAR: Open-label, phase 2 study investigating the efficacy and safety of the addition of oral-azacitidine to salvage treatment by gilteritinib in subjects ≥18 years of age with relapsed/refractory FLT3-mutated acute myeloid leukemia
Sponsor French Innovative Leukemia Organization
- Start (EU)
- Latest update
- Estimated end
- Not reported
Questions about this trial experience
What services are recorded for Centre Hospitalier Universitaire De Lille?
The 2026-10-09 snapshot links Centre Hospitalier Universitaire De Lille to 4 distinct CTIS trials. Recorded services include Laboratory services, Biobanking, Clinical monitoring, Project management. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Centre Hospitalier Universitaire De Lille?
The most frequently recorded therapeutic areas are Haematological Malignancies. Recorded phases include Phase 3. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Centre Hospitalier Universitaire De Lille conducted?
The linked trials record locations in 14 countries, including France, Austria, Belgium, Germany, Denmark. These are trial locations, not confirmed office locations or countries where Centre Hospitalier Universitaire De Lille delivered services.
What can this page tell me about Centre Hospitalier Universitaire De Lille's trial experience?
Browse 4 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Centre Hospitalier Universitaire De Lille. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Centre Hospitalier Universitaire De Lille